Natera is trading 4.52% up at $343.00, with no confirmed company-specific announcement identified for September 8, 2026.
- The latest notable company news was September 1 clinical-validation data for Signatera in lymphoma, predating this move.
- Reported pre-market activity was limited, at approximately 700 shares.
- Broader sentiment was mixed-to-lower, but major indices did not show a sufficiently strong same-direction decline to establish a macro cause.